PharmaLogic Holdings has signed a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings. Financial terms were not disclosed.
The Springfield facility is a radiopharmaceutical manufacturing site with a track record in theranostic manufacturing, research and clinical development. Its team will join Agilera, PharmaLogic's therapeutic CDMO franchise, upon completion of the transaction. The deal also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition expands PharmaLogic's capacity to manufacture radiopharmaceutical therapeutics in the U.S. Agilera brings more than 15 years of experience supporting the development and commercial launch of radioligand therapies and currently supplies an alpha therapy to more than 30 countries. With the Springfield facility, PharmaLogic becomes the first therapeutic CDMO to offer a transatlantic platform, giving partners an end-to-end solution for RLTs from early clinical development through commercial launch and global supply.
CEO Etienne Montagut said the acquisition strengthens Agilera's capabilities in radioligand therapies and expands its U.S. capacity, and that the Springfield team will help scale operations to meet growing demand from partners and their patients.
Lantheus CEO Mary Anne Heino said PharmaLogic has been an important manufacturing partner for Lantheus' PET products and is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on the foundation while supporting supply of Lantheus' newly approved radiotherapeutic.
The transaction is subject to regulatory review and other customary closing conditions. The parties will continue to operate independently until closing.